In studying the therapeutic evidence of innovative drug treatments, increasing attention is being devoted to differentiating between results that indicate no significant differences among the treatments under examination ("no proof of difference") and results that demonstrate the therapeutic equivalence among the treatments ("proof of no difference"). It is well known that this latter conclusion is more informative than the former because "proof of no difference" is a conclusive result whereas "no proof of difference" is an inconclusive one \[[@CR1]--[@CR3]\].

No such analysis has thus far been conducted concerning dipeptidylpeptidase-4 (DPP-4) inhibitors that represent a pharmacological class increasingly employed in patients with type 2 diabetes.

In this study, we re-analyzed the clinical material presented in the most recent and most exhaustive systematic review in this area \[[@CR4]\] to quantify the degree of therapeutic equivalence for DPP-4 inhibitors given in this disease condition as monotherapy or in combination with metformin.

Our clinical material included the results of all direct and indirect meta-analytical comparisons that Craddy and co-workers \[[@CR4]\] have published in their recent systematic review on this topic. Testing equivalence is particularly straightforward when the information on margins is combined with standard Forest plots \[[@CR5], [@CR6]\]. Margins represent a threshold between clinically relevant incremental benefits and irrelevant ones, and can be retrieved from statistical power information of original trials.

We have applied this approach to evaluate the equivalence of monotherapy with alogliptin, linagliptin, saxagliptin, sitagliptin or vildagliptin versus placebo (Fig. [1](#Fig1){ref-type="fig"}a) and the equivalence of the same agents in combination with metformin versus metformin alone (Fig. [1](#Fig1){ref-type="fig"}b). The end point was HbA~1c~ change from baseline. The equivalence margins were set at ±0.25% change in HbA~1c~ according to Buse et al. \[[@CR7]\]. The clinical material that was reported by Craddy et al. \[[@CR4]\] is presented in their Table 5.Fig. 1Forest plot with equivalence margins: relative treatment effect of five DDP4 inhibitors evaluated as monotherapy versus placebo (**a**) or as combination with metformin versus metformin alone (**b**). Incremental effectiveness is expressed according to the end point of HbA~1c~ change from baseline. In both *panels*, the *horizontal bars* (alogliptin in *violet*, linagliptin in *yellow*, saxagliptin in *red*, sitagliptin in *green*, vildagliptin in *blue*) indicate the two-sided 95% confidence interval for the meta-analytic estimate (*solid square*) of relative treatment effect. The equivalence interval is comprised between the two *vertical dotted lines* and is centered around the value of weighted incremental effectiveness (*vertical solid line*) across the five agents (−0.71 in **a**, −0.61 in **b**). The equivalence test is applied based on the equivalence intervals that reflect the margins reported by Buse et al. \[[@CR7]\]. The criterion for demonstrating equivalence (at alpha level = 2.5%) is when the entire 95% confidence interval remains within the equivalence interval. *P* values for equivalence were: **a** (*top* to *bottom*) 0.038, 0.024, 0.177, 0.002, 0.023; **b** (*top* to *bottom*) 0.103, 0.01, 0.003, 0.001, 0.002

In our first analysis (Fig. [1](#Fig1){ref-type="fig"}a), our equivalence testings found an equivalent treatment effect for linagliptin, sitagliptin, and vildagliptin given as monotherapy when compared with one another; the effect of saxagliptin did not satisfy the equivalence criterion, while the result for alogliptin was borderline. In our second analysis (Fig. [1](#Fig1){ref-type="fig"}b), the combination of the same five agents in comparison with metformin alone showed an equivalent effect for linagliptin, saxagliptin sitagliptin, and vildagliptin whereas the combination including alogliptin did not satisfy the equivalence criterion.

It should be kept in mind that, in patients with type 2 diabetes, all international guidelines advocate metformin first. Hence, our analysis on monotherapy with DPP-4 inhibitors had more speculative than a practical interest. In contrast, the analysis evaluating the combination of DPP-4 inhibitors with metformin had some practical interest. In fact, four of the five DPP-4 inhibitors clearly showed to have the same effectiveness; the fifth agent---alogliptin---failed to meet the less important criterion of the "left" margin (so that its superiority cannot be excluded), but, however, fully satisfied the criterion of being non-inferior in comparison with the "right" margin.

While the safety of these drugs is another important factor for defining their respective role in comparative terms, the evidence on this point seems to be more difficult to interpret because of the diversity of the safety end points and their relatively low frequency of occurrence \[[@CR4]\].

In conclusion, although our analyses have entirely been based on the same clinical material already published by Craddy et al. \[[@CR4]\], our results convey original information to better interpret the effectiveness of these agents in terms of equivalence. When treatment with a DPP-4 inhibitor in combination with metformin is started in a given patient, our findings indicate that the magnitude of the reduction in HbA~1c~ cannot represent the main criterion for selecting a specific agent in a given patient, since the expected improvement is essentially the same across these agents. Other criteria should, therefore, prevail, including the dosing schedule, the profile of adverse effects, and, last but not least, the cost.
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